Shares of Masimo Co. (NASDAQ:MASI) have been given an average recommendation of “Buy” by the eight brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $149.75.
A number of research firms have recently issued reports on MASI. UBS Group lifted their price target on shares of Masimo from $147.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. Needham & Company LLC reiterated a “buy” rating and set a $158.00 price target (up from $155.00) on shares of Masimo in a research report on Tuesday, May 7th. Piper Jaffray Companies lifted their price target on shares of Masimo from $140.00 to $148.00 and gave the company an “overweight” rating in a research report on Tuesday, May 7th. Zacks Investment Research upgraded shares of Masimo from a “hold” rating to a “buy” rating and set a $153.00 price target for the company in a research report on Wednesday, May 8th. Finally, BidaskClub upgraded shares of Masimo from a “buy” rating to a “strong-buy” rating in a research report on Tuesday.
Shares of MASI stock traded up $5.68 during midday trading on Monday, reaching $147.08. 8,522 shares of the company traded hands, compared to its average volume of 450,203. Masimo has a 1-year low of $95.85 and a 1-year high of $143.10. The company has a market cap of $7.71 billion, a price-to-earnings ratio of 48.66, a PEG ratio of 2.73 and a beta of 1.12.
Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Monday, May 6th. The medical equipment provider reported $0.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.04. Masimo had a net margin of 22.49% and a return on equity of 18.61%. The company had revenue of $231.70 million during the quarter, compared to the consensus estimate of $223.67 million. During the same period last year, the firm earned $0.75 EPS. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. As a group, equities research analysts expect that Masimo will post 3.12 earnings per share for the current year.
In related news, insider Jon Coleman sold 2,000 shares of Masimo stock in a transaction that occurred on Wednesday, February 27th. The stock was sold at an average price of $135.00, for a total transaction of $270,000.00. Following the completion of the transaction, the insider now directly owns 13,201 shares in the company, valued at approximately $1,782,135. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Ramshorst David J. Van sold 1,845 shares of Masimo stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $140.00, for a total value of $258,300.00. Following the transaction, the chief accounting officer now owns 1,695 shares of the company’s stock, valued at $237,300. The disclosure for this sale can be found here. Insiders have sold a total of 33,722 shares of company stock valued at $4,582,310 over the last 90 days. Insiders own 11.50% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Claybrook Capital LLC purchased a new stake in Masimo in the 4th quarter worth approximately $25,000. West Oak Capital LLC purchased a new stake in Masimo in the 1st quarter worth approximately $28,000. Coastal Investment Advisors Inc. purchased a new stake in Masimo in the 1st quarter worth approximately $31,000. Ruggie Capital Group purchased a new stake in Masimo in the 4th quarter worth approximately $33,000. Finally, Quantamental Technologies LLC purchased a new stake in Masimo in the 4th quarter worth approximately $43,000. Hedge funds and other institutional investors own 81.79% of the company’s stock.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
See Also: What is the float in trading stocks?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.